Jeffry L. Dean

3.2k total citations
25 papers, 1.9k citations indexed

About

Jeffry L. Dean is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jeffry L. Dean has authored 25 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jeffry L. Dean's work include Cancer-related Molecular Pathways (13 papers), Advanced Breast Cancer Therapies (6 papers) and Effects and risks of endocrine disrupting chemicals (3 papers). Jeffry L. Dean is often cited by papers focused on Cancer-related Molecular Pathways (13 papers), Advanced Breast Cancer Therapies (6 papers) and Effects and risks of endocrine disrupting chemicals (3 papers). Jeffry L. Dean collaborates with scholars based in United States, Australia and Finland. Jeffry L. Dean's co-authors include Erik S. Knudsen, A. Kathleen McClendon, Karen E. Knudsen, Chellappagounder Thangavel, Agnieszka K. Witkiewicz, Chris Reed, Adam Ertel, Stephen L. Dobson, Matthew J. Schiewer and Jonathan F. Goodwin and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Gastroenterology.

In The Last Decade

Jeffry L. Dean

25 papers receiving 1.9k citations

Peers

Jeffry L. Dean
Kevin J. Wu United States
Heidi S. Erickson United States
Beverly D. Smolich United States
Marian Grade Germany
James V. Alvarez United States
Ying Su China
Xia Luo China
Jeffry L. Dean
Citations per year, relative to Jeffry L. Dean Jeffry L. Dean (= 1×) peers Jochen Dahm‐Daphi

Countries citing papers authored by Jeffry L. Dean

Since Specialization
Citations

This map shows the geographic impact of Jeffry L. Dean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffry L. Dean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffry L. Dean more than expected).

Fields of papers citing papers by Jeffry L. Dean

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffry L. Dean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffry L. Dean. The network helps show where Jeffry L. Dean may publish in the future.

Co-authorship network of co-authors of Jeffry L. Dean

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffry L. Dean. A scholar is included among the top collaborators of Jeffry L. Dean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffry L. Dean. Jeffry L. Dean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kim, Stephanie, et al.. (2022). Harmonization of transcriptomic and methylomic analysis in environmental epidemiology studies for potential application in chemical risk assessment. Environment International. 164. 107278–107278. 4 indexed citations
2.
Patlewicz, Grace, Jeffry L. Dean, Catherine F. Gibbons, et al.. (2021). Integrating publicly available information to screen potential candidates for chemical prioritization under the Toxic Substances Control Act: A proof of concept case study using genotoxicity and carcinogenicity. Computational Toxicology. 20. 100185–100185. 5 indexed citations
3.
Pradeep, Prachi, Richard Judson, David M. DeMarini, et al.. (2021). An evaluation of existing QSAR models and structural alerts and development of new ensemble models for genotoxicity using a newly compiled experimental dataset. Computational Toxicology. 18. 100167–100167. 16 indexed citations
4.
Lizarraga, Lucina E., Jeffry L. Dean, Jonas Kaiser, et al.. (2019). A case study on the application of an expert-driven read-across approach in support of quantitative risk assessment of p,p’-dichlorodiphenyldichloroethane. Regulatory Toxicology and Pharmacology. 103. 301–313. 11 indexed citations
6.
Augello, Michael A., Lisa D. Berman-Booty, Richard W. Carr, et al.. (2015). Consequence of the tumor‐associated conversion to cyclin D1b. EMBO Molecular Medicine. 7(5). 628–647. 15 indexed citations
7.
Schrecengost, Randy S., Jeffry L. Dean, Jonathan F. Goodwin, et al.. (2013). USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression. Cancer Research. 74(1). 272–286. 99 indexed citations
8.
Goodwin, Jonathan F., Matthew J. Schiewer, Jeffry L. Dean, et al.. (2013). A Hormone–DNA Repair Circuit Governs the Response to Genotoxic Insult. Cancer Discovery. 3(11). 1254–1271. 265 indexed citations
9.
Dean, Jeffry L. & Karen E. Knudsen. (2013). The Role of Tumor Suppressor Dysregulation in Prostate Cancer Progression. Current Drug Targets. 14(4). 460–471. 13 indexed citations
10.
Dean, Jeffry L., A. Kathleen McClendon, & Erik S. Knudsen. (2012). Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition. Journal of Biological Chemistry. 287(34). 29075–29087. 120 indexed citations
11.
Augello, Michael A., Craig J. Burd, Ruth Birbe, et al.. (2012). Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. Journal of Clinical Investigation. 123(1). 493–508. 35 indexed citations
12.
McClendon, A. Kathleen, Jeffry L. Dean, Dayana B. Rivadeneira, et al.. (2012). CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle. 11(14). 2747–2755. 134 indexed citations
13.
Dean, Jeffry L., A. Kathleen McClendon, Theresa E. Hickey, et al.. (2012). Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 11(14). 2756–2761. 182 indexed citations
14.
Dean, Jeffry L., Chellappagounder Thangavel, A. Kathleen McClendon, Chris Reed, & Erik S. Knudsen. (2010). Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 29(28). 4018–4032. 305 indexed citations
15.
Ertel, Adam, Jeffry L. Dean, Hallgeir Rui, et al.. (2010). RB-pathway disruption in breast cancer. Cell Cycle. 9(20). 4153–4163. 127 indexed citations
16.
McClendon, A. Kathleen, Jeffry L. Dean, Adam Ertel, & Erik S. Knudsen. (2009). Differential Impact of Tumor Suppressor Pathways on DNA Damage Response and Therapy-Induced Transformation in a Mouse Primary Cell Model. PLoS ONE. 5(1). e8558–e8558. 2 indexed citations
17.
Dean, Jeffry L., A. Kathleen McClendon, Kristy R. Stengel, & Erik S. Knudsen. (2009). Modeling the effect of the RB tumor suppressor on disease progression: dependence on oncogene network and cellular context. Oncogene. 29(1). 68–80. 12 indexed citations
18.
Stengel, Kristy R., et al.. (2008). RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents. Cell Cycle. 7(8). 1095–1103. 19 indexed citations
19.
Xi, Zhiyong, Jeffry L. Dean, Cynthia Khoo, & Stephen L. Dobson. (2005). Generation of a novel Wolbachia infection in Aedes albopictus (Asian tiger mosquito) via embryonic microinjection. Insect Biochemistry and Molecular Biology. 35(8). 903–910. 107 indexed citations
20.
Dean, Jeffry L. & Stephen L. Dobson. (2004). Characterization ofWolbachiaInfections and Interspecific Crosses ofAedes(Stegomyia)polynesiensisandAe.(Stegomyia)riversi(Diptera: Culicidae). Journal of Medical Entomology. 41(5). 894–900. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026